Narrow search
Showing 1 - 10 of 15,164
Cover Image
A Better Way to Generate Comparative-Effectiveness Research
Cannon, Michael F. - 2014
Advocates of a new federal comparative-effectiveness agency argue that such information has characteristics of a public … that government should provide comparative-effectiveness research, nor that government provision would increase social … health insurance and medical professionals, inhibit the types of health plans best equipped to generate comparative-effectiveness …
Persistent link: https://www.econbiz.de/10014212889
Cover Image
Drug Pricing and Risk Sharing Agreements
Capri, Stefano; Levaggi, Rosella - 2008
note we present a specific risk sharing agreement on effectiveness and show how such mechanism is going to affect the … market in the long run. In particular, we will show how the regulator may create a trade off between expected efficacy and …
Persistent link: https://www.econbiz.de/10014217551
Cover Image
Drug Pricing in a Regulated Market
Capri, Stefano; Levaggi, Rosella - 2004
In this article we analyse the problem of determining the price for new drugs in a market where a stringent budget constraint on public expenditure exists and we suggest an innovative methodology to set their prices. The market is characterised by asymmetry of information and a high proportion...
Persistent link: https://www.econbiz.de/10014071880
Cover Image
Shifting the Risk in Pricing and Reimbursement Schemes? A Model of Risk-Sharing Agreements for Innovative Drugs
Capri, Stefano; Levaggi, Rosella - 2011
effectiveness of the drug (i.e. the efficacy resulted in the real medical practice). We assume that the probability of being listed … price is set according to the declared efficacy of the new drug, but if ex post the effectiveness falls short of what … (approved and reimbursed) depends on the relative performance of the new drug in terms of effectiveness and budget required. The …
Persistent link: https://www.econbiz.de/10014181847
Cover Image
Quantifying the Impacts of Limited Supply : The Case of Nursing Homes
Ching, Andrew T.; Hayashi, Fumiko; Wang, Hui - 2016
In this paper, we develop an empirical demand model and an estimation strategy that can account for excess demand, and the unobserved component of product quality. Our methodology allows us to quantify the extent of rationing, price and quality elasticities, and shed light on the potential...
Persistent link: https://www.econbiz.de/10014046544
Cover Image
International Price Regulations in the Pharmaceutical Sector : A Common Model to Sharing the Benefits
Levaggi, Rosella; Capri, Stefano - 2005
In this article we analyse the market for drugs in health care markets where third payers (an insurance company or a government agency) bear the cost and we suggest a common and transparent methodology to set the price for new drugs as well as active principles for which an alternative already...
Persistent link: https://www.econbiz.de/10014028693
Cover Image
Picking Your Patients : Selective Admissions in the Nursing Home Industry
Gandhi, Ashvin - 2021
Do healthcare providers pick their patients? This paper uses patient-level administrative data on skilled nursing facilities in California to estimate a structural model of selective admission practices in the nursing home industry. I exploit within-facility covariation between occupancy and...
Persistent link: https://www.econbiz.de/10013235001
Cover Image
Risk-sharing agreements in pharmaceutical markets
Antoñanzas Villar, Fernando; Juárez-Castelló, Carmelo; … - In: Estudios de economía aplicada : revista promovida por … 31 (2013) 2, pp. 359-378
Persistent link: https://www.econbiz.de/10010207164
Cover Image
Organizational powers : capture of professional jurisdiction in the case of US retail clinics
Galperin, Roman V. - 2011
Innovative technology may reduce organizations’ reliance on professionals in the performance of expert tasks, weakening professions’ control over work. However, professions resist and challenge such innovation, framing it as unsafe and immoral. This paper theorizes a process by which...
Persistent link: https://www.econbiz.de/10009580343
Cover Image
The Use of Mtas to Control Commercialization of Stem Cell Diagnostics and Therapeutics
O'Connor, Sean M. - 2013
While much of the commentary on obstacles to stem cell research focuses on patents, material transfer agreements (MTAs) governed by state contract and property law present equal if not greater challenges to researchers. This Article argues that the life sciences in general, and the stem cell...
Persistent link: https://www.econbiz.de/10012754166